We are live on ! Find out more
CERE

Cerevel Therapeutics Holdings, Inc. Common Stock
CERE

Delisted

CERE was delisted on the 31st of July, 2024.

Back to rankings

62 hedge funds and large institutions have $1.37B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 14

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

7% more funds holding

Funds holding: 58 → 62 (+4)

15% less capital invested

Capital invested by funds: $1.61B → $1.37B (-$234M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
62
Holders Change
+4
Holders Change %
+6.9%
% of All Funds
1.09%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
15
Increased
23
Reduced
14
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$14.6M
2
State Street
State Street
Massachusetts
+$13.6M
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$11.8M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$11.7M
5
WP
Woodline Partners
California
+$5.75M

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$11.4M
2
BC
Boxer Capital
California
-$8.78M
3
EC
EcoR1 Capital
California
-$6.63M
4
DM
Deerfield Management
New York
-$6.38M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$4.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCI
1
Bain Capital Investors
Massachusetts
$832M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$70.2M +$11.7M +798,700 +19%
PA
3
Perceptive Advisors
New York
$63.7M +$1.45M +99,033 +2%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$46.7M +$113K +7,755 +0.2%
Vanguard Group
5
Vanguard Group
Pennsylvania
$44.3M +$1.2M +82,067 +3%
AG
6
Artal Group
Luxembourg
$34.3M +$3.19M +217,900 +10%
RCM
7
RA Capital Management
Massachusetts
$30.2M – – –
Federated Hermes
8
Federated Hermes
Pennsylvania
$26.8M +$14.6M +998,300 +105%
Alkeon Capital Management
9
Alkeon Capital Management
New York
$24M – – –
ABG
10
Ally Bridge Group
New York
$23.7M -$568K -38,850 -2%
Citadel Advisors
11
Citadel Advisors
Florida
$16.8M -$2.27M -154,827 -11%
BlackRock
12
BlackRock
New York
$15.1M +$31.9K +2,180 +0.2%
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$13.9M -$4.81M -329,005 -25%
RSCM
14
Rock Springs Capital Management
Maryland
$13.8M +$89.3K +6,100 +0.6%
State Street
15
State Street
Massachusetts
$12.8M +$13.6M +932,136 New
SFM
16
Sphera Funds Management
Israel
$12.5M +$1.47M +100,575 +12%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$11.4M +$11.8M +809,151 +3,740%
BC
18
Boxer Capital
California
$9.81M -$8.78M -600,000 -46%
Adage Capital Partners
19
Adage Capital Partners
Massachusetts
$8.24M – – –
RI
20
RTW Investments
New York
$6.87M – – –
Geode Capital Management
21
Geode Capital Management
Massachusetts
$6.09M -$219K -14,992 -3%
Millennium Management
22
Millennium Management
New York
$5.85M +$5.65M +386,444 +977%
WP
23
Woodline Partners
California
$5.39M +$5.75M +392,910 New
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$4.07M +$2.59M +176,700 +147%
AAA
25
Affinity Asset Advisors
New York
$3.71M – – –
1
2 3

CERE Hedge Fund Activity: Q1 2021 in Review

62 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q1 2021, worth a combined $1.37B — down 15% from $1.61B a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CERE positions and 11 closed out — a net gain of 4 holders — while 23 added to existing stakes and 14 trimmed.

The largest buyer was Federated Hermes, adding an estimated $14.6M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $11.4M sold.

  • 62 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q1 2021, up from 58 in Q4 2020.
  • Funds reported $1.37B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q1 2021, down 15% quarter-over-quarter.
  • 15 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q1 2021 and 11 closed out, a net change of +4 holders.
  • The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q1 2021 was Federated Hermes, an estimated $14.6M added.
  • The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q1 2021 was Nantahala Capital Management, an estimated $11.4M sold.

Based on aggregated 13F filings for Q1 2021.